INO Key Statistics, Chart & Performance
The current stock price of INO is 1.6 USD. In the past month the price decreased by -22.71%. In the past year, price decreased by -19.19%.
INO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About INO
Company Profile
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 134 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Company Info
INOVIO PHARMACEUTICALS INC
660 W. Germantown Pike, Suite 110
Plymouth Meeting PENNSYLVANIA 19462 US
CEO: J. Joseph Kim
Employees: 134
Phone: 18584103134
INOVIO PHARMACEUTICALS INC / INO FAQ
Can you describe the business of INOVIO PHARMACEUTICALS INC?
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 134 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
What is the stock price of INOVIO PHARMACEUTICALS INC today?
The current stock price of INO is 1.6 USD. The price increased by 0.63% in the last trading session.
What is the dividend status of INOVIO PHARMACEUTICALS INC?
INO does not pay a dividend.
What is the ChartMill technical and fundamental rating of INO stock?
INO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is INO stock listed?
INO stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for INO stock?
INOVIO PHARMACEUTICALS INC (INO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.49).
What is the market capitalization of INO stock?
INOVIO PHARMACEUTICALS INC (INO) has a market capitalization of 109.92M USD. This makes INO a Micro Cap stock.
INO Technical Analysis
INO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INO. Both the profitability and financial health of INO have multiple concerns.
INO Financial Highlights
Over the last trailing twelve months INO reported a non-GAAP Earnings per Share(EPS) of -2.49. The EPS increased by 44.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -155.78% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
INO Forecast & Estimates
10 analysts have analysed INO and the average price target is 7.79 USD. This implies a price increase of 386.62% is expected in the next year compared to the current price of 1.6.
For the next year, analysts expect an EPS growth of 42.3% and a revenue growth -33.27% for INO